These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 8865473

  • 1. Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?
    Hall MC, Roehrborn CG, McConnell JD.
    Semin Urol Oncol; 1996 Aug; 14(3):122-33. PubMed ID: 8865473
    [Abstract] [Full Text] [Related]

  • 2. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J, Högstedt B.
    Scand J Urol Nephrol; 2002 Aug; 36(5):330-8. PubMed ID: 12487736
    [Abstract] [Full Text] [Related]

  • 3. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
    Ramos CG, Carvahal GF, Mager DE, Haberer B, Catalona WJ.
    J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [Abstract] [Full Text] [Related]

  • 5. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Jan; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 6. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT.
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [Abstract] [Full Text] [Related]

  • 7. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H.
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [Abstract] [Full Text] [Related]

  • 8. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
    Keetch DW, Andriole GL, Ratliff TL, Catalona WJ.
    Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
    [Abstract] [Full Text] [Related]

  • 9. Hormonal predictors of prostate cancer.
    Sofikerim M, Eskicorapci S, Oruç O, Ozen H.
    Urol Int; 2007 Dec; 79(1):13-8. PubMed ID: 17627161
    [Abstract] [Full Text] [Related]

  • 10. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 11. The role of prostate-specific antigen in the evaluation of benign prostatic hyperplasia.
    Tchetgen MB, Oesterling JE.
    Urol Clin North Am; 1995 May; 22(2):333-44. PubMed ID: 7539179
    [Abstract] [Full Text] [Related]

  • 12. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll PR, Hricak H, Chen MH, Kurhanewicz J.
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [Abstract] [Full Text] [Related]

  • 13. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 14. The usefulness of prostate specific antigen density as a screening method for prostatic carcinoma.
    Chakrabarti S, Raha K, Bhunia CL, Bhattachary DK.
    J Indian Med Assoc; 2001 Nov; 99(11):627-8, 630. PubMed ID: 12022203
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
    Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W.
    Prostate; 2005 Aug 01; 64(3):240-5. PubMed ID: 15712213
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS, Heyns CF, Van Vuuren SP, Zarrabi AD.
    S Afr J Surg; 2012 Nov 12; 50(4):127-30. PubMed ID: 23217554
    [Abstract] [Full Text] [Related]

  • 17. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M, Bastian M, Steiner M, Zingler C, Müller M, Wolff JM, Seiter H, Schuff-Werner P.
    Anticancer Res; 2000 Nov 12; 20(6D):4995-6. PubMed ID: 11326656
    [Abstract] [Full Text] [Related]

  • 18. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 19. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber MM, Jacobsen SJ.
    J Urol; 2005 Jun 15; 173(6):2048-53. PubMed ID: 15879823
    [Abstract] [Full Text] [Related]

  • 20. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA.
    Cancer; 1997 Jan 01; 79(1):104-9. PubMed ID: 8988733
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.